Dengue Vaccine Development
GSID’s expertise in clinical and product development has been utilized by the
Pediatric Dengue Vaccine Initiative (PDVI), a program of the
International Vaccine Institute in Seoul, Korea. We have been evaluating candidate vaccines, their respective developers and potential manufacturing partners around the world. Our evaluations of development partners have provided PDVI with the necessary input to further the advancement of evaluating dengue vaccines in large-scale trials. We have also been working closely with the
Butantan Institute (Sao Paolo, Brazil) on their dengue vaccine development program.
About Dengue
Dengue fever is a mosquito-borne disease, primarily of children, and prevalent in tropical countries around the world. Dengue fever has severe consequences of hemorrhagic fever and dengue shock and results in substantial morbidity and mortality. There is currently no vaccine available for dengue, although a number of vaccine candidates are in various stages of development. For more information please see:
